BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 28721449)

  • 1. Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.
    Sander FE; Nilsson M; Rydström A; Aurelius J; Riise RE; Movitz C; Bernson E; Kiffin R; Ståhlberg A; Brune M; Foà R; Hellstrand K; Thorén FB; Martner A
    Cancer Immunol Immunother; 2017 Nov; 66(11):1473-1484. PubMed ID: 28721449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
    Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
    J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
    Brune M; Castaigne S; Catalano J; Gehlsen K; Ho AD; Hofmann WK; Hogge DE; Nilsson B; Or R; Romero AI; Rowe JM; Simonsson B; Spearing R; Stadtmauer EA; Szer J; Wallhult E; Hellstrand K
    Blood; 2006 Jul; 108(1):88-96. PubMed ID: 16556892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
    Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
    Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance.
    Grauers Wiktorin H; Aydin E; Christenson K; Issdisai N; Thorén FB; Hellstrand K; Martner A
    Oncoimmunology; 2021; 10(1):1944538. PubMed ID: 34367728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.
    Sander FE; Rydström A; Bernson E; Kiffin R; Riise R; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB; Martner A
    Oncotarget; 2016 Feb; 7(7):7586-96. PubMed ID: 26863635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated frequencies of CD4⁺ CD25⁺ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia.
    Shenghui Z; Yixiang H; Jianbo W; Kang Y; Laixi B; Yan Z; Xi X
    Int J Cancer; 2011 Sep; 129(6):1373-81. PubMed ID: 21105040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
    Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
    Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
    Thorén FB; Romero AI; Brune M; Hellstrand K
    Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.
    Nilsson MS; Hallner A; Brune M; Nilsson S; Thorén FB; Martner A; Hellstrand K
    Hum Vaccin Immunother; 2020; 16(1):109-111. PubMed ID: 31242079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells.
    Han Y; Dong Y; Yang Q; Xu W; Jiang S; Yu Z; Yu K; Zhang S
    Front Immunol; 2018; 9():2227. PubMed ID: 30319662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
    Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
    Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
    Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feedback loop of immune regulation by CD4+CD25+ Treg.
    Jung YJ; Seoh JY
    Immunobiology; 2009; 214(4):291-302. PubMed ID: 19327546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway.
    Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D
    Front Immunol; 2018; 9():1274. PubMed ID: 29922294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
    Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
    J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity.
    Chen X; Du Y; Huang Z
    Immunol Lett; 2012; 148(1):83-9. PubMed ID: 23000301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
    Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
    Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
    Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A
    Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Th17 and CD4
    Xiang M; Guo L; Ma Y; Li Y
    Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2405-2410. PubMed ID: 28167485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.